Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

KP-100IT

Phase 3Small molecule

KKringle Pharma, Inc.

1

Indications

3

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Spinal Cord Injury (SCI)Not yet recruiting

Acute Spinal Cord Injury (SCI)Phase 3

Not yet recruiting

Timeline

Expected Milestones

Q4 2028

Phase 3Not yet recruiting

Acute Spinal Cord Injury (SCI)

NCT07722962

Clinical

Trials by Indication[1]

Spinal Cord Injury2 trials

Phase 3 Study of KP-100IT in Subjects With Acute Spinal Cord Injury

Unknown status·KKringle Pharma, Inc.·Phase 3·NCT04475224·25 enrolled

Phase I/II Study of KP-100IT in Acute Spinal Cord Injury

Completed·KKringle Pharma, Inc.·Phase 1/2·NCT02193334·45 enrolled

Acute Spinal Cord Injury (SCI)1 trial

An Additional Phase 3, Multicenter Study of Intrathecal Administration of KP-100IT in Subjects With Acute Spinal Cord Injury

Not yet recruiting·KKringle Pharma, Inc.·Phase 3·NCT07722962·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for KP-100IT. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — KP-100IT compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for KP-100IT. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Kringle Pharma, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: KKringle Pharma, Inc.

Related News